Education
School — Major — Degree | Duration |
---|---|
臺北醫學大學 — 醫學科學研究所(畢) — 博士 Doctorate, Graduate Institute of Medical Sciences, Taipei Medical University |
2013/08 — 2017/06 |
臺北醫學大學 — 醫學科學研究所(畢) — 碩士 Master, Graduate Institute of Medical Sciences, Taipei Medical University |
2007/08 — 2009/06 |
臺北醫學大學 — 藥學系(畢) — 學士 Bachelor, Department of Pharmacology, Taipei Medical University |
2003/08 — 2007/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
學士後醫學系 School of Post-Baccalaureate Medicine | Assistant Professor | 2023/02/01 — |
Extramural Experience
Discipline
NO | Discipline | Expertise |
---|---|---|
1 | 生物醫農類 Biology, Medicine and Agriculture | 藥理及毒理 Pharmacology and Toxicology |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
醫材領域、眼部臨床疾病
Area(s) of Expertise & Research
神經退化暨視網膜退化疾病; 神經發炎; 眼部血管新生; 基因治療; 藥物開發; 分子訊息
Neurodegeneration and Retinal Degeneration; Neuroinflammation; Ocular Angiogenesis; Gene Therapy; Drug Discovery; Signaling Transduction
Publication
NO | Publication |
---|---|
1 | New acorane-sesequiterpenes and anti-retinoblastoma constituents from the marine algicolous fungus Trichoderma harzianum NTU2180 guided by molecular networking strategy. New acorane-sesequiterpenes and anti-retinoblastoma constituents from the marine algicolous fungus Trichoderma harzianum NTU2180 guided by molecular networking strategy. |
2 | A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. |
3 | 真菌成份 Theissenolactone B 透過抑制RPE之金屬蛋白酶 9和小膠質細胞活化進而保護sodium iodate誘導的 AMD 模型 Retinal protection by fungal product theissenolactone B in a sodium iodate-induced AMD model through targeting retinal pigment epithelial matrix metalloproteinase-9 and microglia activity. |
4 | 應用明膠顆粒封裝的 TAK1 抑製劑演滴劑型可緩減角膜血管新生 Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization. |
5 | 綜合多體學分析指出 microRNA-143 可能成為治療視網膜血管新生之藥物 An Integrative Multi-Omics Analysis Reveals MicroRNA-143 as a Potential Therapeutic to Attenuate Retinal Angiogenesis. |
6 | 阻斷 TAK1 可能為視網膜血管新生之療法 TAK1 blockade as a therapy for retinal neovascularization. |
7 | 二氧化鈦納米粒子通過激活 ADAM17 和 claudin-5 降解而損害血視網膜屏障和視網膜電生理 Titanium dioxide nanoparticles impair the inner blood-retinal barrier and retinal electrophysiology through rapid ADAM17 activation and claudin-5 degradation. |
8 | 調控式 Flt23k 基因療法應用於干預視網膜血管新生 A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization. |
9 | 體內遞送 CRISPR/Cas 系統的方法:最近的更新和未來的展望 Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect. |
10 | CRISPR/CasRx 之 RNA 編輯方法 Methods for CRISPR/CasRx-Mediated RNA Editing. |
11 | Ergosta-7,9(11),22-trien-3β-ol 減緩腦出血後腦損傷和 BV-2 小膠質細胞活化 Ergosta-7,9(11),22-trien-3β-ol Alleviates Intracerebral Hemorrhage-Induced Brain Injury and BV-2 Microglial Activation. |
12 | HDAC/HSP90 抑製劑 G570 透過減少 VEGF 產生以減弱藍光誘導的 RPE 細胞遷移和小鼠血管新生 The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. |
13 | 血管新生性眼病的基因治療 Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update. |
14 | Hirsutanol A 減緩脂多醣誘導之基質金屬蛋白酶 9 的表達和細胞因子的產生,並改善內毒素血症引起的急性行為異常和急性肺損傷 Hirsutanol A Attenuates Lipopolysaccharide-Mediated Matrix Metalloproteinase 9 Expression and Cytokines Production and Improves Endotoxemia-Induced Acute Sickness Behavior and Acute Lung Injury. |
15 | 真菌衍生之視網膜保護成分 theissenolactone C 可抑制MMP-9 而改善其介導之青光眼損傷 The fungus-derived retinoprotectant theissenolactone C improves glaucoma-like injury mediated by MMP-9 inhibition. |
16 | HADC8 抑製劑 WK2-16 治療脂多醣誘導的小鼠腦神經炎症和小膠質細胞激活 HADC8 Inhibitor WK2-16 Therapeutically Targets Lipopolysaccharide-Induced Mouse Model of Neuroinflammation and Microglial Activation. |
17 | Theissenolactone C 通過緩減眼部炎症和膠質細胞活化以保護內毒素誘導之葡萄膜炎 Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation. |
18 | Haloperidol抑制人類單核細胞中的NF-kB路徑以降低基質金屬蛋白酶 9 的表達 Haloperidol Abrogates Matrix Metalloproteinase-9 Expression by Inhibition of NF-B Activation in Stimulated Human Monocytic Cells. |
19 | 天然視網膜保護成分chrysophanol 減緩 N-methyl-N-nitrosourea誘導小鼠視網膜退化之感光細胞凋亡 The natural retinoprotectant chrysophanol attenuated photoreceptor cell apoptosis in an N-methyl-N-nitrosourea-induced mouse model of retinal degenaration. |
20 | 定期曝露於仿智慧型手機之低亮度藍光會透過 Bcl-2/BAX 依賴性細胞凋亡路徑誘導視網膜損傷 Periodic Exposure to Smartphone-Mimic Low-Luminance Blue Light Induces Retina Damage Through Bcl-2/BAX-Dependent Apoptosis |
21 | 光學斷層掃描分析指出長期局部使用 Fluorometholone 會誘導大鼠的神經節細胞損傷 Long-term Fluorometholone Topical Use Induces Ganglion Cell Damage in Rats Analyzed With Optical Coherence Tomography. |
22 | N-2-(4-bromophenyl) ethyl caffeamide抑制核內NF-kappaB下調節人類單核球之基質金屬蛋白酵素9 生成 Nuclear-targeted inhibition of NF-kappaB on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. |
Project
NO |
YEAR — Source — No — Type
Project Name
|
Duration |
---|---|---|
1 |
116 — N 國科會(原科技部) — NSTC114-2320-B-037-018-MY3 — 1 個人型
探討海洋真菌代謝產物誘導化學重編程以再生視網膜神經元之潛力(3/3)( )
|
2027/08/01 ~ 2028/07/31 |
2 |
115 — N 國科會(原科技部) — NSTC114-2320-B-037-018-MY3 — 1 個人型
探討海洋真菌代謝產物誘導化學重編程以再生視網膜神經元之潛力(2/3)( )
|
2026/08/01 ~ 2028/07/31 |
3 |
114 — N 國科會(原科技部) — NSTC114-2320-B-037-018-MY3 — 1 個人型
探討海洋真菌代謝產物誘導化學重編程以再生視網膜神經元之潛力(1/3)( )
|
2025/08/01 ~ 2028/07/31 |
4 |
114 — NK 高醫-中山合作計畫 — — 1 個人型
探討芸香科植物萃取物於治療眼部癌症之潛力(To investigate the anti-retinoblastoma activities of Rutaceae plant extractant)
|
2025/01/01 ~ 2025/12/31 |
5 |
113 — N 國科會(原科技部) — NSTC113-2320-B-037-020 — 1 個人型
探討木樨科植物萃取物透過調節視網膜上皮細胞及內皮細胞治療眼後部疾病之潛力( )
|
2024/08/01 ~ 2025/07/31 |
6 |
113 — NK 高醫-中山合作計畫 — NK113P34 — 1 個人型
篩選木犀科植物萃取物於治療視網膜母細胞瘤(The screening of Oleaceae extractant in retinoblastoma treatment)
|
2024/01/01 ~ 2024/12/31 |
7 |
113 — Q 新聘教師計畫(校內) — KMU-Q114005 —
探討海洋真菌代謝產物於治療糖尿病性視網膜炎之潛力( )
|
2025/01/01 ~ 2025/12/31 |
8 |
112 — DK 前瞻重點(原校院) — KMU-DK(A)113005 —
探討糖尿病體循環及眼局部利鈉尿胜肽於糖尿病性視網膜炎之角色( )
|
2024/01/01 ~ 2024/12/31 |
9 |
112 — Q 新聘教師計畫(校內) — KMU-Q113005 —
探討枸杞中藥複方治療糖尿病視網膜炎之潛力( )
|
2024/01/01 ~ 2024/12/31 |
10 |
112 — Z 大專學生研究計畫及博士後 — NSTC113-2813-C-037-046-B — 8 大專學生研究計畫
113年度大專學生研究計畫-施雅婷(藥學4)( )
|
2024/07/01 ~ 2025/02/28 |
11 |
111 — N 國科會(原科技部) — NSTC112-2320-B-037-008 — 1 個人型
探討具調節利鈉尿胜肽受器C之木犀科植物萃取物於治療視網膜循環疾病之潛力( )
|
2023/05/01 ~ 2024/04/30 |